GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teligent Inc (OTCPK:TLGTQ) » Definitions » Cyclically Adjusted PB Ratio

Teligent (Teligent) Cyclically Adjusted PB Ratio : (As of May. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Teligent Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Teligent Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Teligent's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teligent Cyclically Adjusted PB Ratio Chart

Teligent Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Teligent Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Teligent's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Teligent's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teligent's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teligent's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Teligent's Cyclically Adjusted PB Ratio falls into.



Teligent Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Teligent's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2021 is calculated as:

For example, Teligent's adjusted Book Value per Share data for the three months ended in Jun. 2021 was:

Adj_Book=Book Value per Share/CPI of Jun. 2021 (Change)*Current CPI (Jun. 2021)
=-0.634/114.6314*114.6314
=-0.634

Current CPI (Jun. 2021) = 114.6314.

Teligent Quarterly Data

Book Value per Share CPI Adj_Book
201109 1.571 95.727 1.881
201112 1.455 95.213 1.752
201203 1.291 96.783 1.529
201206 1.168 96.819 1.383
201209 0.850 97.633 0.998
201212 1.086 96.871 1.285
201303 1.026 98.209 1.198
201306 0.966 98.518 1.124
201309 1.070 98.790 1.242
201312 1.615 98.326 1.883
201403 1.636 99.695 1.881
201406 1.519 100.560 1.732
201409 6.256 100.428 7.141
201412 7.409 99.070 8.573
201503 8.783 99.621 10.106
201506 14.111 100.684 16.066
201509 13.721 100.392 15.667
201512 12.596 99.792 14.469
201603 12.537 100.470 14.304
201606 12.011 101.688 13.540
201609 11.620 101.861 13.077
201612 10.662 101.863 11.999
201703 10.952 102.862 12.205
201706 10.939 103.349 12.133
201709 9.960 104.136 10.964
201712 8.381 104.011 9.237
201803 7.532 105.290 8.200
201806 7.311 106.317 7.883
201809 6.640 106.507 7.147
201812 3.426 105.998 3.705
201903 1.898 107.251 2.029
201906 1.245 108.070 1.321
201909 -0.029 108.329 -0.031
201912 -0.986 108.420 -1.042
202003 -5.908 108.902 -6.219
202006 -7.007 108.767 -7.385
202009 -6.272 109.815 -6.547
202012 -5.063 109.897 -5.281
202103 -0.533 111.754 -0.547
202106 -0.634 114.631 -0.634

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Teligent  (OTCPK:TLGTQ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Teligent Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Teligent's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teligent (Teligent) Business Description

Traded in Other Exchanges
N/A
Address
105 Lincoln Avenue, Buena, NJ, USA, 08310
Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.
Executives
Joseph Benesch officer: VP, Controller, PAO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
Alyssa Lozynski officer: Interim CFO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310
William S Marth director 236 GROVE STREET, WELLESLEY MA 02482
Philip K Yachmetz officer: EVP, Chief Legal Off, Corp Sec 501 LAFAYETTE AVE WYCKOFF NJ 07481
R Carter Pate director 5739 WORTHAM LANE, DALLAS TX 75252
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Carole Ben-maimon director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Sabatino Thomas J Jr director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
John E Celentano director C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Steven H Koehler director C/O THE MEDICINES CO, 5 SYLVAN WAY, PARSIPPANY NJ 07054
Keith James officer: Prin Acct Officer Controller 105 LINCOLN AVENUE BUENA NJ 08310
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Donald V Weir 10 percent owner SANDERS MORRIS HARRIS, 600 TRAVIS, HOUSTON TX 77002
Timothy B. Sawyer officer: CEO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310